GET DAILY SIGNALSCME Group (CME) Reports Record Q3 Revenue and Volume Growth
Key Takeaways
- CME Group reported record third-quarter revenue of $1.74 billion, up 13% year over year.
- Adjusted earnings per share (EPS) reached $3.02, up 13% and above the consensus estimate of $2.98.
- Average daily volume (ADV) hit a record 29.4 million contracts, up 16%, with double-digit growth across all six asset classes.
- Market data revenue climbed to an all-time record of $243 million, its 34th consecutive quarter of growth.
- The company returned roughly $1 billion to shareholders through dividends and buybacks.
Why These Results Matter in the Current Market Environment
CME Group operates some of the world's largest derivatives exchanges and serves as a central venue for managing risk across interest rates, equities, currencies, energy, metals, and agriculture. Its results act as a barometer for global trading activity, since higher volatility and shifting central-bank policy tend to drive more volume through its platforms. The third quarter of 2026 took place against a backdrop of persistent geopolitical uncertainty and market volatility, conditions that historically favor increased hedging activity. This report therefore matters not only for CME shareholders but also for investors seeking a read on the health of global capital markets heading into year-end.
Breaking Down the Reported Figures
CME Group reported total revenue of $1.74 billion for the quarter ended September 30, 2026, up 13% from $1.54 billion a year earlier and the highest third-quarter revenue in company history. Clearing and transaction fees rose to $1.38 billion, while market data and information services revenue climbed 20% to a record $243 million.
Adjusted diluted EPS came in at $3.02, up 13% year over year and above the consensus estimate of $2.98. Adjusted operating income reached $1.2 billion, up 15%, translating to a 69.4% adjusted operating margin. On a GAAP basis, net income was $1.04 billion, with diluted EPS of $2.89.
The standout driver was volume. Average daily volume (ADV) reached a record 29.4 million contracts, up 16%, with double-digit growth across every asset class. Equity products led the way, up 23%, and international ADV grew 22% to a record 9 million contracts per day. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The results were widely viewed as a beat, with revenue and adjusted EPS both surpassing consensus estimates by roughly 1% to 1.4%. Investor attention focused less on the modest beat and more on the breadth of the growth: double-digit volume increases in every asset class and record open interest, which reached 128 million contracts at quarter-end and has since exceeded 133 million. Management's disclosure that fourth-quarter volume was tracking 17% above the prior year's record reinforced the view that momentum is carrying into the current period. Sentiment also benefited from disciplined capital returns, with nearly $1 billion distributed to shareholders during the quarter.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will watch whether CME Group can sustain its volume momentum into year-end. Management noted that fourth-quarter average daily volume was running 17% ahead of last year's record quarter and that full-year volume was tracking 12% ahead of the prior record, pointing to the potential for another record year.
A key catalyst on the horizon is the scheduled December launch of CME Securities Clearing, ahead of the SEC's Treasury clearing mandate. This expansion into securities clearing represents a new growth avenue that could diversify revenue beyond traditional futures and options clearing.
Other factors worth monitoring include the pace of the company's cloud migration with Google Cloud, which is expected to begin moving markets in late 2027, and license-fee costs tied to equity volume. Margin and capital-efficiency dynamics will also matter, as interest-rate levels influence investment income from cash held at the clearing house. As always, sustained volatility and hedging demand across global markets will remain the core driver of CME Group's top-line performance. From what I see, the breadth of growth across asset classes suggests the momentum could hold if volatility persists.
Exploring AI Tools in My Research Process
I often turn to Tickeron’s AI-powered tools when analyzing earnings reports like this one. The AI Screener helps me quickly filter stocks and ETFs by technical patterns, fundamentals, and performance metrics, making it easier to compare opportunities across sectors and identify patterns that might otherwise take hours to spot manually. It has become a regular part of how I cross-check volume trends and peer performance before forming a fuller view.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CME in upward trend: 10-day moving average broke above 50-day moving average on October 14, 2026
The 10-day moving average for CME crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on CME as a result. In 56 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for CME just turned positive on October 08, 2026. Looking at past instances where CME's MACD turned positive, the stock continued to rise in 25 of 48 cases over the following month. The odds of a continued upward trend are 52%.
CME moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 171 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 41%.
CME broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CME entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 27 (best 1 - 100 worst), indicating outstanding price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.010) is normal, around the industry mean (3.969). P/E Ratio (24.961) is within average values for comparable stocks, (16.930). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). Dividend Yield (0.018) settles around the average of (0.019) among similar stocks. CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of securities and commodity exchanges
Industry FinancialPublishingServices
Advertisement